Regeneron Announces Upcoming 2013 Investor Conference Presentations

TARRYTOWN, N.Y., Feb. 19, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) will webcast management presentations at the following investor conferences:

  • Citi 2013 Global Healthcare Conference; Dyslipidemia Panel on Tuesday, February 26, 2013.  The session is scheduled for 1:30 p.m. Eastern Time.
  • RBC Capital Markets' 2013 Global Healthcare Conference on Wednesday, February 27, 2013.  The presentation is scheduled for 9:30 a.m. Eastern Time.
  • Barclays Global Healthcare Conference on Tuesday, March 12, 2013.  The presentation is scheduled for 2:30 p.m. Eastern Time.

The sessions may be accessed through the Company's web site, www.regeneron.com, on the 'Events and Presentations' page.  An archived version of the presentations will be available for 30 days.

About Regeneron Pharmaceuticals, Inc.
Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma.  For additional information about the company, please visit www.regeneron.com.

Contact Information:




Michael Aberman, M.D.

Peter Dworkin

Investor Relations

Corporate Communications                          

914.847.7799

914.847.7640             

michael.aberman@regeneron.com

peter.dworkin@regeneron.com

SOURCE Regeneron Pharmaceuticals, Inc.



RELATED LINKS
http://www.regeneron.com

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.